Lv1
26 积分 2024-06-02 加入
Identification of pathogenic PD‐1+CD8+ T cells for effective chimeric antigen receptor therapy in a murine model of Sjögren's disease
1天前
已完结
AB0502 CELLULAR AND PROTEOMIC CHANGES FOLLOWING ADMINISTRATION OF PERESOLIMAB, IN A PHASE 2A TRIAL IN RHEUMATOID ARTHRITIS
1天前
求助中
Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: a phase 2a induction trial
10天前
已完结
P911 Development and Characterization of SPY002, a Novel Extended Half-life Monoclonal Antibody Drug Candidate Targeting TL1A for the Treatment of IBD
22天前
已完结
Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial
22天前
已完结
A Noncomitogenic CD2R Monoclonal Antibody Induces Apoptosis of Activated T Cells by a CD95/CD95-L-Dependent Pathway
1个月前
已完结
Translational study of the regulatory mechanism by which immune synapses enhance immune cell function
1个月前
已完结
Structure-based identification of inhibitors disrupting the CD2–CD58 interactions
1个月前
已完结
Cis interactions between CD2 and its ligands on T cells are required for T cell activation
1个月前
已完结
The emerging role of deubiquitylating enzyme USP21 as a potential therapeutic target in cancer
2个月前
已完结
皖公网安备34019202002308
